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Abstract This study aims to estimate the incidence and
costs of osteoporosis-related fractures in The Netherlands
in 2010 and project them to 2030. The incidence and costs
of five different types of fractures (spine, hip, upper
extremity, lower extremity, wrist/distal forearm, other)
were derived from claims data of all Dutch healthcare
insurers. Given that fracture-codes in claims data do not
indicate whether fractures are related to osteoporosis, we
used a large dataset with DXA measurements to attribute
fractures to osteoporosis. Future projections used four
scenarios: (1) demographic, (2) demographic ? annual
trend in incidence rates, (3) demographic ? annual trend in
incidence rates ? annual trend in costs, and (4) treatment.
Of all registered fractures, 32 % was attributed to osteo-
porosis (36 % in women and 21 % in men). Over time
(2010–2030) the increase in incidence of osteoporosis-re-
lated fractures was estimated to be 40 % (scenario 1); for
the hip 60–79 % (scenario 1–2). In 2010, approximately
€200 million was spent on treatment of osteoporosis-re-
lated fractures, most on fractures of the hip followed by
wrist/distal forearm. In both men and women, the excess
costs due to osteoporosis-related fractures were highest for
hip fractures (€11,000–€13,000 per person), followed by
spine fractures (€6000–€7000).The costs for osteoporosis-
related fractures were projected to increase with 50 % from
2010 to 2030 (scenario 1); for the hip 60–148 % (scenario
1–3). Pharmacotherapeutic prevention can lead to cost-
savings of €377 million in 2030 (scenario 1 and 4 com-
bined). The projected increase in incidence and costs of
osteoporosis-related fractures calls for a wider use of pre-
vention and treatment.
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Introduction
The prevalence of osteoporosis in The Netherlands is
estimated at 1.9 per 1000 for men and 16.1 per 1000 for
women and it increases strongly with age [1]. Osteoporosis
increases the risk of fractures [2]. An osteoporosis-related
fracture at higher age substantially impairs the quality of
life and increases the costs of healthcare [3].
Important risk factors and prognostic factors of osteo-
porosis and osteoporosis-related fractures include age, sex,
bone mineral density, spine fracture in the past, a recent
none-spine fracture, a non-recent fracture above the age of
50, and a low body weight [2]. Although the guidelines
strongly recommend diagnosing osteoporosis by dual-
Electronic supplementary material The online version of this
article (doi:10.1007/s00223-015-0089-z) contains supplementary
material, which is available to authorized users.
& Maureen P. M. H. Rutten-van Mo¨lken
m.rutten@bmg.eur.nl
1 Institute of Medical Technology Assessment, Erasmus
University, P.O.-Box 1738, 3000 DR Rotterdam,
The Netherlands
2 Maastricht University Medical Center?, Maastricht,
The Netherlands
3 VieCuri Medical Center Noord Limburg, Venlo,
The Netherlands
4 Department of Clinical Pharmacy & Toxicology, Maastricht
University Medical Center?, Maastricht, The Netherlands
5 MRC Epidemiology Lifecourse Unit, Southampton General
Hospital, Southampton, UK
6 Utrecht Institute for Pharmaceutical Sciences, Utrecht,
The Netherlands
123
Calcif Tissue Int
DOI 10.1007/s00223-015-0089-z
energy X-ray absorptiometry (DXA) measurements in
patients with clinical risk factors, the implementation of
this recommendation highly varies between settings [4]. As
a result, the prevalence estimates are affected by consid-
erable underrepresentation and underdiagnosis and only a
part of the target group will be treated for osteoporosis [5].
Treatment of osteoporosis consists of lifestyle recom-
mendations, vitamin D supplementation and specific anti-
osteoporosis medication [5]. Bisphosphonates are the most
widely prescribed anti-osteoporosis medication.
However, therapy adherence is low. Low adherence not
only has medical implications, but also economical
because the treatment of a (subsequent) fracture is rather
costly [2, 3] and a fracture may cause permanent disability
associated with high healthcare use.
With an ageing population, and a growing proportion of
people of 80 years or older, the societal burden of osteo-
porosis-related fractures is deemed to be increasing [6].
However, we do not know to what extent, because there is
a lack of detailed information on the gender and age-
specific incidence and healthcare costs of osteoporosis-re-
lated fractures needed to enable future projections [2].
Previous studies in The Netherlands have reported the costs
of fractures without attributing a proportion of these costs
to osteoporosis [7]. This study aims at giving more insight
in the number of osteoporosis-related fractures and the
associated healthcare costs in The Netherlands. Moreover,
projections will be made of the number of osteoporosis-
related fractures and the related costs in the near future. We
have specifically investigated the incidence of fractures
among patients aged 50 years or older, the proportion of
these fractures that is due to osteoporosis, the healthcare
costs due to osteoporosis-related fractures and the projec-
tions of osteoporosis-related fractures and related costs
over time between 2010 and 2030.
Methods
Overall Incidence of Fractures
Data Source
Data on the incidence of fractures were obtained from the
VEKTIS database. This health insurance claims database
includes the healthcare expenditures of 99 % of the 16.5
million Dutch citizens. Since 2006, the Dutch citizens have
a single compulsory healthcare insurance for the basic
benefit package that includes primary care, outpatient
hospital care, inpatient hospital care and medications; they
may have supplementary insurance on top of that. Insurers
are free to contract providers based on negotiations on
price and quality and patients choose the provider they
prefer. Health insurers are obliged to accept all new
applicants for the basis benefit package and they are not
allowed to differentiate the premiums of the basic benefit
package according to risk profile. The government controls
the quality, accessibility and affordability of health care.
Inpatient and outpatient hospital care is paid by the insurers
through an elaborate diagnosis-related groups (DRG) sys-
tem. In essence, hospitals receive a fixed payment per
Diagnosis-Treatment-Combination (DBC). This DBC sys-
tem was implemented in The Netherlands in 2005. Cur-
rently, nationwide DBCs are registered in the VEKTIS
database. The exact services provided in a particular DBC
are not registered separately. Due to a steep learning curve
in the registration of DBCs in the early years after the
introduction and changes in the DBC registration system,
VEKTIS data before 2009 are less valid and data from
2012 onwards were incomplete on the date of data
extraction for this study (i.e. February 05, 2014). There-
fore, we used data from the VEKTIS database for the years
2009, 2010, and 2011.
Study Population
To estimate the incidence rates of fractures, we selected
from the VEKTIS database all subjects aged 50 years or
over, with at least one DBC code for a fracture as recorded
by orthopaedic specialists or general surgeons. Fracture
DBC codes were categorized according to the following
fracture sites: upper extremity, wrist/distal forearm, spine,
lower extremity, hip, and other fractures. The list of codes
is provided in the Online Appendix. The VEKTIS data
were grouped by gender and 5-year age categories (i.e.
51–55, 56–60, 61–65, 66–70, 71–75, 76–80, 81–85 years,
and older than 85 years). Absolute and relative incidence
(defined as the number per 100,000 person years) of frac-
tures per year were calculated for each age category in men
and women. To calculate the relative incidence, we used
the size of the population, as reported by Statistics
Netherlands (CBS) [8].
Incidence of Osteoporosis-Related Fractures
In order to attribute fractures to osteoporosis, we used a
dataset of the VieCuri Medical Center, an expert center on
metabolic bone disease, in the southern part of The
Netherlands. This dataset contained bone-mineral-density
(BMD) measures (T-scores) of people 50 years or older
who visited the hospital due to a fracture between 2009 and
2011 [9, 10]. In line with the WHO, we defined osteo-
porosis as a BMD of 2.5 or more standard deviations below
that of a healthy 30-year old adult (i.e. a T-score of B -2.5
SD) as measured by DXA at the lumbar spine, femoral
neck or total hip [11]. All fractures in patients with a
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T-score of B-2.5 SD were defined as being related to
osteoporosis [5, 11]. To calculate the total number of
osteoporosis-related fractures, the percentage of fractures
with a T-score B -2.5 SD was applied to the total number
of fractures obtained from the VEKTIS data. This was done
separately for each fracture site (i.e. hip, spine, wrist/distal
forearm, upper extremity, lower extremity, and other).
Healthcare Costs
Healthcare costs in the years 2009–2011 were also
obtained from VEKTIS data. These costs included all
inpatient and outpatient hospital costs (per DBC), costs of
physical therapy, occupational therapy, general practitioner
contacts and medication. We obtained the mean gender and
age-specific healthcare costs of people with a fracture of a
particular type and compared them to the mean gender and
age-specific healthcare costs of people without a fracture.
This way, we calculated the excess healthcare costs of a
patient with a fracture compared to a patient without a
fracture, by gender and age category. To estimate the total
healthcare costs due to osteoporosis-related fractures, we
multiplied the absolute incidence of osteoporosis-related
fractures in each gender, age, and fracture category with
the mean excess healthcare cost in the same category.
Costs were expressed in Euros (€).
Future Projections and Scenarios
Using the incidence and costs of osteoporosis-related
fractures in 2010 as a reference four future scenarios are
presented that project the incidence and costs of osteo-
porosis-related fractures from 2010 to 2030:
1. A demographic scenario for incidence and costs for all
osteoporosis-related fractures
In this scenario, the gender and age-specific incidence
rate per 100,000 in 2010 was multiplied by the number of
citizens in each gender and age class that is projected by
the CBS for the years 2015, 2020, 2025, and 2030 [8].
2. A demographic scenario for incidence that additionally
included the annual trend in the incidence of hip
fractures that was observed between 2000 and 2010.
The annual trend in incidence of hip fractures was cal-
culated separately for each 5-year age- and gender category
using data from the National Medical Register of Dutch
hospitals (LMR) from 2000 to 2010 [12]. We had to use
data from the LMR to estimate this trend because the
VEKTIS data covered only 3 years, which is insufficient to
estimate a trend. The LMR is a national register of hospital
admissions, including admissions due to fractures. How-
ever, the LMR is less representative than the VEKTIS data
because the number of missing records in the LMR has
increased since 2005, probably because of the stepwise
introduction of the DBC system in hospitals [13]. Com-
parison of the number of fractures in the LMR data for
2009, 2010, and 2011 with the number of fractures in the
VEKTIS data revealed that only the number of hip frac-
tures was similar. All other fracture types seem systemat-
ically underreported in the LMR data compared to the
VEKTIS data. We therefore decided to estimate only the
trend in hip fractures.
3. A demographic scenario for costs of osteoporosis-
related hip fractures that additionally included the
annual trend in the incidence of hip fractures and the
annual trend in healthcare costs.
The annual increase in healthcare costs is obtained from
the Dutch Healthcare Authority (NZa). This increase was
estimated to be 1.6 % per year over the period 2006–2010.
This is the increase in prices after correction for the increase
in the amount of healthcare resource utilization [14].
4. A treatment scenario for costs of osteoporosis-related
hip fractures. We applied a treatment-induced relative
risk reduction for osteoporosis-related fractures to the
results from scenario 3.
The relative risk reductions of interventions preventing
osteoporosis-related fractures were obtained from the
Cochrane Review database [15]. We used the estimate for
the most prominent intervention applied in The Nether-
lands, i.e. alendronate [5, 16].With the obtained risk
reduction an estimate could be given of future cost savings
due to treatment.
Results
Over the years 2009–2011, the VEKTIS database con-
tained on average 5,616,439 people of 50 years or older per
year. Over these years an annual average of 114,116
patients with a fracture was identified, divided into 15 %
hip fractures, 6 % fractures of the spine, 22 % distal
forearm/wrist fractures, 26 % upper extremity fractures,
24 % lower extremity fractures, and 7 % other fractures.
Incidence Osteoporosis-Related Fractures
From the VieCuri Medical Center, DXA measurements of
1984 patients older than 50 years (529 male, 1455 female)
who presented themselves with a recent fracture were
available. Of these patient 8.6 % had a hip fracture, 8.9 %
a fracture of the spine, 17.3 % a distal forearm/wrist
fracture, 33.6 % a fracture located at the upper extremity,
22.5 % a fracture located at the lower extremity, and 9.2 %
F. J. B. Lo¨tters et al.: Current and Future Incidence and Costs of Osteoporosis-Related Fractures…
123
another kind of fracture. Table 1 shows the percentage of
fractures attributed to osteoporosis (i.e. fractures in patients
with a T-score of -2.5 or less at lumbar spine, femoral
neck or total hip).
Overall, 32 % of the fractures could be attributed to
osteoporosis. This percentage was considerably higher for
women than for men, i.e. 36 % versus 21 %, respectively.
More than 50 % of hip fractures and spine fractures in
women were attributed to osteoporosis.
In Table 2 the absolute and relative incidence of all
fractures and osteoporosis-related fractures are presented
for 2010. To obtain the number of osteoporosis-related
fractures the gender and age-specific number of fractures of
each type were multiplied by the gender and fracture-
specific percentages as summarized in Table 1. In
Tables A1, A2, and A3 of the Online Source the incidence
of fractures by 5-year age- and gender class is given.
When looking at all fractures, regardless of their rela-
tionship to osteoporosis, the number of women with a
fracture was more than twice the number of men. When
looking at osteoporosis-related fractures, the incidence was
more than four times higher in women than in men. In men,
osteoporosis-related fractures of the hip were most fre-
quent, whereas in women osteoporosis-related fractures of
the wrist/distal forearm were most frequent.
Projections of Incidence of Osteoporosis-Related
Fractures
In the demographic scenario, the age- and gender-specific
incidence rates per 100,000 in 2010 were applied to the
projected numbers of people in the population. Due to
ageing of the population, the total number of osteoporosis-
related fractures increased from 38,666 in 2010 to 53,993
in 2030. The increase in incidence of osteoporosis-related
fractures from 2010 to 2030 was 40 %; 48 % in men and
38 % in women.
In Fig. 1, the demographic projections from 2010 to
2030 are presented by type of osteoporosis-related fracture.
In both men and women, osteoporosis-related fractures
of the hip showed the largest increase in incidence. In
women, this increase was 53 % whereas in men this
increase was 86 %.
In Table A4 of the Online Source, the annual trend in
incidence of hip fractures per 100,000 persons from 2000
until 2010 is presented. When we added this trend to the
demographic scenario, the steeper increase in osteoporosis-
related hip fractures in men as compared to women was
even more pronounced. In men, the number of osteoporo-
sis-related hip fractures in 2030 was 32 % higher in the
demographic plus incidence trend scenario compared with
the demographic scenario. In women, the difference
between the two scenarios was only 5 %.
Costs of Osteoporosis-Related Fractures
Table 3 shows that the annual healthcare costs for osteo-
porosis-related fractures in 2010 were almost 200 million
Euros a year; 77 % of these costs were due to osteoporosis-
related fractures in women. In both men and women, the
costs of osteoporosis-related hip fractures were the largest;
56 % of total costs in men and 52 % of total costs in women.
Approximately 80 % of all healthcare costs incurred by
patients with an osteoporosis-related hip fracture could be
attributed to treatment and care directly related to this frac-
ture. For osteoporosis-related spine fractures, this percentage
was approximately 70 %, whereas for fractures of the wrist/
distal forearm it was only 33 %.
In both women and men, the healthcare costs due to
osteoporosis-related hip fractures (approximately €11,000–
€13,000 per person) exceeded those of other osteoporosis-
related fractures substantially. The healthcare costs of
osteoporosis-related spine fractures were the second high-
est category with approximately €5500–€7000 per fracture.
In Fig. 2, the costs of osteoporosis-related fractures in
2010 are presented per 100,000 person years in each age
class. In both men and women costs of osteoporosis-related
fractures increased with age. In men, costs at age 85? were
1.5 times as high as the costs at age 51–55. In women, costs
at age 85? were 2.5 times as high as the costs at age
51–55. In both men and women, the difference between the
youngest and oldest age category was highest for other
fractures and spine fractures.
Projections of Costs of Osteoporosis-Related
Fractures
Due to ageing of the population, the overall increase in
costs of osteoporosis-related fractures between 2010 and
2030 were 50 %. For women this increase was 45 %,
Table 1 Number and percentage of fractures with osteoporosis (T-
score B -2.5 at lumbar spine, femoral neck or total hip) by gender
and fracture type
Men Women
n (N) % n (N) %
Spine 18 (54) 33.3 65 (123) 52.8
Hip 22 (60) 36.7 60 (108) 55.6
Upper extremity 24 (137) 17.5 180 (529) 34.0
wrist/distal forearm 9 (58) 15.5 100 (285) 35.1
Lower extremity 26 (146) 17.8 77 (300) 25.7
Other 12 (73) 16.4 44 (109) 40.4
Total 111 (528) 21.0 526 (1454) 36.2
n = Number of fractures attributed to osteoporosis based on T-score
of DXA; N = total number of fractures
F. J. B. Lo¨tters et al.: Current and Future Incidence and Costs of Osteoporosis-Related Fractures…
123
whereas for men it was 66 % (demographic projection).
After osteoporosis-related hip fractures, with a cost
increase of 52 and 84 % for women and men, respectively,
the costs of osteoporosis-related spine and other fractures
increased most (ranging from 43 to 56 %).
Figure 3 shows the change in costs of osteoporosis-re-
lated hip fractures over time for the demographic scenario,
the demographic plus trend in incidence scenario, and the
demographic plus trend in incidence and trend in costs
scenario. For the first scenario, the increase in healthcare
costs over time was 52 % in women and 84 % in men.
For the demographic scenario including the incidence
trend, these percentages were 62 and 157 %, respectively.
When the trend in costs was added (i.e. the upper line),
costs increased with 119 % for women and 237 % for men
between 2010 and 2030.
Cost savings by Intervention
The bisphosphonate alendronate is the most frequently
prescribed medication for osteoporosis in The Netherlands
[17]. A Cochrane review [18] showed that the use of
Fig. 1 Projected number of osteoporosis-related fractures over time by type of fracture (in women and men); demographic scenario (d) and
demographic trend (d ? t) in incidence scenario (only for osteoporosis-related hip fractures)
Table 2 Incidence of all fractures and osteoporosis-related fractures, by gender and fracture type, in 2010
Fracture type All fractures Osteoporosis-related
fractures (absolute)
Osteoporosis-related
fractures (/100,000)
Male Spine 2285 761 27
Hip 5219 1915 69
Upper extremity 9924 1737 62
Wrist/distal forearm 5227 810 29
Lower extremity 8461 1506 54
Other 3094 507 18
Total 34,210 7236 260
Female Spine 4459 2354 76
Hip 12,543 6974 226
Upper extremity 20,742 7052 228
Wrist/distal forearm 22,120 7764 251
Lower extremity 20,094 5164 167
Other 5251 2121 69
Total 85,209 31,429 1018
Male and Female Spine 6744 3115 53
Hip 17,762 8889 151
Upper extremity 30,666 8789 150
Wrist/distal forearm 27,347 8574 146
Lower extremity 28,555 6670 114
Other 8345 2629 45
Total 119,419 38,666 659
F. J. B. Lo¨tters et al.: Current and Future Incidence and Costs of Osteoporosis-Related Fractures…
123
Table 3 Annual healthcare costs for osteoporosis-related fractures in 2010
Fracture
type
Mean healthcare costs for a
person with a fracture
(fracture and non- fracture
related)*
Mean healthcare costs
for a person without a
fracture (non-fracture
related)*
%cost
related to
fractures*
Mean healthcare
costs due to
osteoporosis-related
fracture per
person*
Total healthcare costs due
to osteoporosis-related
fractures in The
Netherlands**
Men Spine €10,786.03 €3578.88 67 €7207.15 €5,483,953.08
Hip €16,708.45 €4098.85 75 €12,609.60 €24,152,080.40
Upper
extremity
€5463.60 €2862.24 47 €2601.35 €4,517,772.00
Wrist/
distal
forearm
€4751,15 €3005.04 37 €1746.11 €1,414,670.73
Lower
extremity
€6301.98 €2793.01 56 €3508.97 €5,284,706.88
Other €7832.67 €3167.51 60 €4665.17 €2,367,180.95
Total €43,220,364.04
Women Spine €8834.83 €3258.86 63 €5575.97 €13,127,801.27
Hip €14,545.30 €3534.72 76 €11,010.57 €76,786,727.38
Upper
extremity
€5610.96 €2903.45 48 €2707.51 €19,094,139.49
Wrist/
distal
forearm
€4426.40 €2941.75 34 €1484.65 €11,527,023.52
Lower
extremity
€6034.66 €2718.38 55 €3316.27 €17,125,767.07
Other €7603.95 €3257.15 58 €4346.80 €9,221,309.75
Total €146,882,768.48
Men and
Women
Spine €9495.93 €3367.29 64 €6128.65 €18,611,754.35
Hip €15,180.89 €3700.48 76 €11,480.41 €100,938,807.77
Upper
extremity
€5563.27 €2890.11 48 €2673.16 €23,611,911.49
Wrist/
distal
forearm
€4488.47 €2953.85 34 €1534.63 €12,941,694.25
Lower
extremity
€6113.87 €2740.50 55 €3373.37 €22,410,473.95
Other €7688.75 €3223.91 58 €4464.84 €11,588,490.70
Total €190,103,132.51
* Weighted average over the 5-year age classes within each fracture type
** Determined by the incidence figures presented in Table 2
Fig. 2 Costs of osteoporosis-related fractures in 2010 per 100,000 person years in each age class
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alendronate (10 mg/day) reduced the risk of osteoporosis-
related fractures by 16–45 %, yielding relative risks of 0.60
(95 % CI 0.40–0.92) for hip fracture, 0.55 (95 % CI
0.45–0.67) for spine fracture, and 0.84 (95 % CI
0.74–0.94) for non-spine fracture. These relative risks were
used as an indicator of the potential effect size of preven-
tive interventions.
Applying the above-mentioned effect-sizes to the num-
bers presented in Fig. 3, the cumulative cost savings in the
period from 2010 until 2030 were estimated to be 377
million Euro (280 million for women and 97 million for
men). Costs due to osteoporosis-related hip fractures could
be decreased with 258 million, osteoporosis-related spine
fractures with 52 million and other osteoporosis-related
fractures with 67 million.
Discussion
This study showed that of all registered fractures in The
Netherlands, 32 % (36 % in women and 21 % in men)
could be attributed to osteoporosis. This resulted in an
incidence of osteoporosis-related fractures of 1018 per
100,000 for women and 260 per 100,000 for men in 2010.
Between 2010 and 2030, the total number of osteoporosis-
related fractures was projected to increase with 40 % (de-
mographic scenario). Hip fractures were the most frequent
type of osteoporosis-related fractures, with a projected
increase that was higher in men (86 %) than in women
(53 %) (demographic scenario).
In 2010, Dutch healthcare insurers spent approximately
€200 million on treatment of osteoporosis-related fractures.
55 % of these costs were due to osteoporosis-related hip
fractures. The increase in costs with age was steepest for
spine fractures, where the costs in the oldest female age
group were 2.5 times as high as in the youngest female age
group. The costs of osteoporosis-related fractures were
projected to increase with 50 % between 2010 and 2030
(demographic scenario). The increase in costs over time
was larger for men than for women, 66 and 45 %,
respectively. Taking into account the annual trend in
incidence and the trend in healthcare costs in general, the
costs for osteoporosis-related hip fractures in 2030 were
projected to be €168 million for women and €81 million for
men.
For the demographic projections, we used the gender-
and age-specific incidence rate of 2010 and kept it constant
over time. Hence, the increase in the number of fractures is
due to ageing of the population. The estimated trend in
incidence rate that we put on top of the demographic
projection was based on the yearly change in incidence rate
of hip fractures between 2000 and 2010 within each age
category. Hence, this trend is not due to ageing but, for
example, due to an increase in the prevalence and/or
severity of osteoporosis.
In our study, we defined an osteoporosis-related fracture
as a fracture that occurred while the DXA measurement
afterwards showed a T-score of B -2.5. Another approach
often used in studies is to consider all fractures from low
energy trauma as being related to osteoporosis [19]. The
merit of this approach is that is recognizes thatmany fragility
fractures occur at less extreme BMD values. However, the
definition of a low energy fall as a fall from a standing height
or less, or a trauma that in a healthy individual would not give
rise to fracture, is hard to measure objectively. Hence, the
assessment of BMD is most frequently used to define an
osteoporosis-related fracture. Related to the discussion about
the definition of an osteoporosis-related fracture is the dis-
cussion about diagnosis of a spinal fracture. A spinal fracture
can either be clinically diagnosed (without X-ray) or mor-
phometrically (diagnosed with X-ray) [20, 21]. In this study,
no distinction could be made between these diagnosis types.
However, based on clinical practice, most of the vertebral
fractures registered by orthopaedic and trauma surgeons in
Fig. 3 Estimated costs of
osteoporosis-related hip
fractures till 2030 (in men and
women); demographic scenario,
demographic ? incidence trend
scenario, and
demographic ? incidence
trend ? costs trend scenario
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The Netherlands will be clinically diagnosed fractures, since
systematic evaluation for morphometric fractures is not the
current practice. Furthermore, it is known that especially
morphometric spinal fractures are often undetected and
therefore underdiagnosed [20, 21]. This implicates that in
our study the cost for treatment of spinal fractures is probably
underestimated.
A major strength of our study is that we had almost
complete claims data on fractures, because the VEKTIS
database covers 99 % of the 16.5 million Dutch citizens.
We could combine this with DXS scan data to attribute a
proportion of these fractures to osteoporosis.
The DXS data were obtained from the VieCuri Medical
Center, an expert center on metabolic bone disorders, in the
southern part of The Netherlands. This dataset contained
approximately 70 % of all fracture patients, i.e. those that
were seen at the fracture liaison service (FLS) and agreed
to be examined for osteoporosis with a DXA scan.
Approximately 30 % of patients were not able or willing to
participate in the FLS. These ‘‘non- attenders’’ appeared to
be significantly older and had more hip fractures than the
attenders [22]. This might have induced a selection bias,
which has probably led to an underestimation of osteo-
porosis-related fractures. The DXS data of the VieCuri
Medical Center are part of a study among five large hos-
pitals in The Netherlands that offer a FLS. Although dif-
ferences between the patients included in the FLSs exist,
from a clinical point of view, these differences were small,
indicating that patient enrollment was quite similar
between FLSs [4]. In this regard, the database on DXA
measurements that we used can be considered representa-
tive for The Netherlands.
The VEKTIS claims database also has some limitations.
It only contains the healthcare expenditures reimbursed by
the health insurance companies. Long-term residential care
costs or costs made for home care were not included. These
costs may be substantial. A Dutch cost of illness study that
uses a top-down approach to allocate costs to diseases [7]
reported that 54 % of the costs of hip fractures were due to
costs of care given in a hospital and 37 % due to long-term
residential care. We estimated that the costs of hospital
care for all osteoporosis-related fractures were €151 mil-
lion. Applying the percentages from the Dutch Costs of
Illness study to the €151 million hospital care cost in our
study (37 %/54 %*151 million) an additional €103 million
needs to be added for long-term residential care. This
would increase our total cost estimate from €190 to €293
million for all osteoporosis-related fractures in 2010.
The VEKTIS database includes claims data covered by
the obligatory basic insurance or the voluntary supplemen-
tary insurance. Physical therapy is partly reimbursed from
the basic insurance but mostly from the supplementary
insurance. Costs of physical therapy by patients without
supplementary insurance will be paid by the patients them-
selves. These out-of-pocket costs are not included in our
calculations. However, we are convinced that this accounts
only for a small fraction of the total healthcare expenditure
for osteoporosis-related fractures because approximately
90 %of the insured did have such a supplementary insurance
in 2010 [23].
Furthermore, the use of DBC-data might induce under-
reporting when patients have multiple fractures. Generally,
only one fracture DBC can be registered in the same per-
iod. This underreporting is probably less prominent for hip
fractures than for the other clinical fractures.
There is a large variation in the incidence of osteo-
porosis-related fractures between countries. Age- and sex-
specific risks of hip fracture differ more than 10-fold, even
within Europe [2]. It is hypothesized that this is related to
differences in socio-economic prosperity, which in turn
may be related to low levels of physical activity. However,
the frequency of osteoporosis-related fractures is rising in
many countries, primarily due to increased longevity of the
population. Our estimates of the future increase in costs
were well in line with a large European study in which an
increase in costs of osteoporosis-related fractures of 25 %
were presented for all EU27 countries. For The Nether-
lands this European study projected an increase of 30 %
until 2025 [2]. In our study, the overall increase in
healthcare costs from 2010 until 2025 were 37 %.
Remarkably, the increase in healthcare costs over time was
greater for men than for women. This can probably be
explained by a stronger increase in remaining life expec-
tancy at age 65, because the difference between women
and men in life expectancy at age 65 decreased from
3.2 years in 2010 to 2.0 years in 2030 [24]. This gender
difference in the future increase in fractures was also seen
in the aforementioned European study [2].
Using a bisphosphonate (alendronate) as medication to
prevent fractures will save approximately €258 million for
hip fractures, €52 million for spine fractures, and €67
million for other fractures in the period 2010–2030,
assuming adequate medication persistence. Alendronate is
recommended as one of the first treatment options for the
primary prevention of osteoporosis-related fragility frac-
tures [5, 25]. In The Netherlands, within the group of
bisphosphonates, alendronate accounts for 57 % of the
total number of defined daily doses that are dispensed [17].
However, adherence to bisphosphonates is a problem. Half
of the patients diagnosed with osteoporosis do not adhere
to the prescription after 1 year [2, 5], whereas bisphos-
phonates are prescribed mostly for 5 years [5]. This non-
adherence increases the risk of a follow-up fracture.
In conclusion, with an incidence of 39,000 per year and
concomitant healthcare costs of at least €200 million
osteoporosis-related fractures are a considerable burden for
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Dutch society. Projections of incidence and healthcare
costs over time indicate that this burden will increase by
40–50 % between 2010 and 2030. Future healthcare
expenditures can be reduced by applying bisphosphonates
in preventing the occurrence of osteoporosis-related
fractures.
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